Business Standard

Lockdown-hit corn starch makers find silver lining in downstream pharma

Although pharma accounts for 10-15% of corn starch supplies, manufacturers are looking to partly make up for loss in production, as offtake has received some support from the crash in input corn price

Migrants undergo thermal screening at Lalgarh Junction before they board a special train to their native place Madhubani (Bihar), during the ongoing COVID-19 lockdown, in Bikaner
Premium

Migrants undergo thermal screening at Lalgarh Junction before they board a special train to their native place Madhubani (Bihar), during the ongoing COVID-19 lockdown, in Bikaner

Virendra Singh Rawat Lucknow
The domestic corn starch industry, whose capacity utilisation is down by nearly 50 per cent owing to the covid-19 lockdown, has found a silver lining in the downstream pharmaceutical space, which is among the sectors largely insulated from the pandemic crisis.

Although pharmaceuticals account for 10-15 per cent of corn starch supplies, manufacturers are looking to partly make up for the loss in production, as offtake has received some support from the crash in the input corn prices owing to the bumper crop this season.


Corn starch

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 28 2020 | 4:12 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com